Blog
![](https://haystackmrd.com/wp-content/uploads/2023/10/featured-image2.jpg)
The importance of truncal somatic mutations in MRD testing
October 2, 2023
Haystack MRD™ prioritizes truncal somatic mutations—those mutations that are present at the initial formation of a tumor, or the trunk of the cancer evolutionary tree.
![Tumor-naive versus tumor-informed](https://haystackmrd.com/wp-content/uploads/2023/09/featured-image3.jpg)
Tumor-naive versus tumor-informed approaches to MRD testing
September 8, 2023
One of the most critical differentiators among minimal residual disease (MRD) tests is whether they are tumor-informed or whether they are tumor-naive.
![Dynamic-blog-post-featured-image](https://haystackmrd.com/wp-content/uploads/2023/05/Dynamic-blog-post-featured-image-1.jpg)
Haystack MRD™: Proven clinical utility
May 31, 2023
The landmark DYNAMIC study is the first prospective, randomized, interventional trial to demonstrate the clinical benefit of MRD testing to guide adjuvant therapy
![DNA-readout-featured-image](https://haystackmrd.com/wp-content/uploads/2023/05/DNA-readout-featured-image-1.jpg)
DNA input and number of mutations tracked: a balancing act
May 19, 2023
Haystack MRD™ strikes the right balance of DNA molecules interrogated and number of mutations tracked for optimizing test efficiency and sustainability